Chronic Pain affects over 1.5 billion individuals in the world with most common treatment, opioids, being characterized by a long list of side effects that can include psychological addiction. Due to these dangerous effects, the World Health Organization (WHO) has established detailed pharmacological guidelines to treat chronic pain in both children and adults.
The development of a treatment that can act locally on the inflammation site, without having an effect on the brain and nervous system has been considered by many the holy grail in pain relief. Nevertheless, the billions of dollars spent on research have yet to provide a clinically approved treatment.
DermoPharm is a German company focused on the development of novel excipients and innovative therapies for severe and chronic diseases. Their team have developed a cutting edge nanocarrier technology and developed a novel method for nanocarrier synthesis that could have a revolutionary impact on the treatment of chronic pain.
Although more common, it is still unusual to see pharmaceutical companies take advantage of crowdfunding platforms to gather the necessary money to finance their research and innovation pipeline. DendroPharm is one them with the company currently seeking 150 000$ in funding at Indiegogo.
We sat down with the Managing Director of DermoPharm, Dr. Sam Moré, and discussed the “For a World with less pain” campaign.
We wanted people all over the world to be involved.
So don’t forget! Visit the “For a World with less pain” campaign page and contribute.